• Publications
  • Influence
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases
The NOD-like receptor (NLR) family, pyrin domain–containing protein 3 (NLRP3) inflammasome is a component of the inflammatory process, and its aberrant activation is pathogenic in inherited disordersExpand
  • 1,002
  • 73
  • PDF
The role of natural product chemistry in drug discovery.
  • M. Butler
  • Medicine
  • Journal of natural products
  • 23 November 2004
Although traditionally natural products have played an important role in drug discovery, in the past few years most Big Pharma companies have either terminated or considerably scaled down theirExpand
  • 1,083
  • 29
  • PDF
Natural products to drugs: natural product derived compounds in clinical trials.
Natural product and natural product-derived compounds that are being evaluated in clinical trials or in registration (current 31 December 2004) have been reviewed. Natural product derived drugsExpand
  • 252
  • 19
Natural products to drugs: natural product-derived compounds in clinical trials.
  • M. Butler
  • Medicine
  • Natural product reports
  • 31 March 2005
Natural product and natural product-derived compounds that are being evaluated in clinical trials or are in registration (as at 31st December 2007) have been reviewed, as well as naturalExpand
  • 660
  • 13
Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice
Oral treatment with a brain-penetrant NLRP3 inhibitor has protective effects in preclinical models of Parkinson’s disease. Systemic inflammasome inhibitor for Parkinson’s disease Brain accumulationExpand
  • 151
  • 9
Natural products--the future scaffolds for novel antibiotics?
Natural products have played a pivotal role in antibiotic drug discovery with most antibacterial drugs being derived from a natural product or natural product lead. However, the rapid onset ofExpand
  • 309
  • 7
Glycopeptide antibiotics: Back to the future
Glycopeptide antibiotics have been a key weapon in the fight against bacterial infections for over half a century, with the progenitors, vancomycin (1) and teicoplanin (2), still used extensively.Expand
  • 103
  • 7
Identification of Chelerythrine as an Inhibitor of BclXL Function*
The identification of small molecule inhibitors of antiapoptotic Bcl-2 family members has opened up new therapeutic opportunities, while the vast diversity of chemical structures and biologicalExpand
  • 152
  • 6
Natural product and natural product derived drugs in clinical trials.
There are a significant number of natural product (NP) drugs in development. We review the 100 NP and NP-derived compounds and 33 Antibody Drug Conjugates (ADCs) with a NP-derived cytotoxic componentExpand
  • 328
  • 4
  • PDF
Antibiotics in the clinical pipeline at the end of 2015
There is growing global recognition that the continued emergence of multidrug-resistant bacteria poses a serious threat to human health. Action plans released by the World Health Organization andExpand
  • 177
  • 4